EE513 Health Economic Evaluation Incorporating Mixture Cure Survival Analysis of Nivolumab Plus Ipilimumab for Previously Untreated Metastatic NSCLC

A Griffiths,R Young, Y Yuan, M Chaudhary,A Lee, J Gordon, P McEwan

Value in Health（2022）

引用 0|浏览0

暂无评分

摘要

This study describes the results of a cost-effectiveness analysis of nivolumab plus ipilimumab (NIVO+IPI) versus platinum doublet chemotherapy (Chemo) in previously untreated metastatic non small-cell lung cancer (NSCLC) using ‘mixture cure’ survival analysis, a statistical method to address circumstances where some patients experience long-term survival and negligible excess mortality.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要